Clinical Trials Directory

Trials / Completed

CompletedNCT02238210

Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy

A Phase IV Safety Trial in Pediatric Patients (Ages 2-5) With Rhinorrhea Associated With a Common Cold or Allergy

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
230 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
All
Age
2 Years – 5 Years
Healthy volunteers
Not accepted

Summary

Study to determine the safety of Atrovent Nasal Spray 0.06% in pediatric patients (ages 2-5 years) with symptoms of rhinorrhea associated with a naturally occurring common cold or from symptoms of rhinorrhea associated with allergies

Conditions

Interventions

TypeNameDescription
DRUGAtrovent®

Timeline

Start date
2002-12-01
Primary completion
2003-05-01
First posted
2014-09-12
Last updated
2014-09-12

Source: ClinicalTrials.gov record NCT02238210. Inclusion in this directory is not an endorsement.